What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Disposable Hemoperfusion Market Size, Share, Growth, And Industry Analysis, By Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion) By Application (Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others), Regional Insights and Forecast From 2025 To 2034
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
DISPOSABLE HEMOPERFUSION MARKET OVERVIEW
The global Disposable Hemoperfusion Market is projected to reach USD 1.66 billion in 2025, steadily progressing to USD 5.4 billion by 2034, with a CAGR of 15.88% from 2025 to 2034.
The United States Disposable Hemoperfusion market size is projected to be USD 0.510 billion in 2025, with Europe at USD 0.433 billion, and China at USD 0.489 billion.
Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment. In this paper, we calculate the hemoperfusion-related medical supplies.
Key Findings
- Market Size and Growth: The global Disposable Hemoperfusion Market is projected to reach USD 1.66 billion in 2025, steadily progressing to USD 5.4 billion by 2034, with a CAGR of 15.88% from 2025 to 2034.
- Key Market Driver: In 2024, more than 6.2 million patients globally underwent hemoperfusion as a secondary treatment for sepsis, liver failure, or autoimmune conditions.
- Major Market Restraint: Clinical data from multiple hospitals reported that up to 23,000 patients experienced complications including platelet reduction and clotting post-hemoperfusion in 2024.
- Emerging Trends: Over 12,000 hospitals across Asia-Pacific integrated resin-based hemoperfusion units in 2024 for targeted toxin and drug overdose filtration procedures.
- Regional Leadership: North America led global usage with over 5.4 million hemoperfusion kits consumed in 2024, with growing integration into ICU protocols.
- Competitive Landscape: Asahi Kasei Corporation distributed over 3.1 million units in 2024 across Japan and Southeast Asia, while Baxter supplied 2.7 million units in the U.S. and Europe.
- Market Segmentation: Charcoal-based hemoperfusion devices accounted for approximately 8.6 million units shipped in 2024, favored for treating drug intoxication and toxin removal.
- Recent Development: In Q4 2024, Jafron Biomedical launched a new dual-layered hemoperfusion cartridge with 2.3 million units distributed within 4 months across China and India.
COVID 19 IMPACT
Growing Research Activities to Impede Market Growth
The global COVID-19 pandemic has been unprecedented and staggering, with the disposable hemoperfusion market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.
The pandemic period saw a rise in research activity. Funding and antibody availability were boosted by an increase in research activities. Product acceptance is boosted by the rising need for vaccines during the coronavirus epidemic. A COVID-19 pandemic epidemic raises businesses' profit margins. Rapid testing and research are in high demand to advance market development. The pandemic's consequences would be researched and examined for both short- and long-term situations. This will help all industry participants, including suppliers, manufacturers, vendors, distributors, and end-users, to develop business plans for the time during the pandemic as well as the time after the pandemic.
LATEST TRENDS
Increasing Demand from Various Applications to Foster Market Growth
The market is projected to be driven in the coming years by the increasing need for the treatment of autoimmune illnesses and the recent appearance of end users for hemoperfusion. Other market-driving variables include a minimal risk of infection, rising public and private investment, and technical developments. The market is expected to be driven in the coming years by rising demand from various applications, such as the treatment of autoimmune illnesses and liver failure, as well as the appearance of new end users for hemoperfusion. The other motivating considerations are a minimal risk of infection, technological breakthroughs, and rising public and private investment.
- According to the U.S. National Institutes of Health (NIH), over 540 hospitals in the U.S. adopted hemoperfusion-based sepsis management as part of their critical care strategy in 2024.
- As per data from the China National Health Commission, more than 1.3 million resin-based hemoperfusion cartridges were used in liver-related detoxification cases in 2024.
DISPOSABLE HEMOPERFUSION MARKET SEGMENTATION
By Type
Based on type, the market is divided into Charcoal Hemoperfusion, Certain Resins Hemoperfusion.
By Application
Based on the application, the market is divided into Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others.
DRIVING FACTORS
Therapeutics and Personalized Procedure to Incite Market Growth
Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment.
Increasing Cases of Diabetes to Stimulate Market Growth
The growing occurrence of numerous viruses and disorders such as sepsis, renal failure, and liver cirrhosis which can be cured by hemoperfusion. The increasing demand for improved and more operative treatment possibilities for several diseases. Technical improvements in hemoperfusion devices and systems that provide enhanced presentation and effectiveness. The increasing number of patients who are overweight or have diabetes, both of which upsurge the danger of emerging organ failures. The rising healthcare spending by governments and private companies to upkeep examination on original treatments using hemoperfusion.
- The World Health Organization (WHO) reported over 10 million global liver disease cases in 2024, increasing reliance on extracorporeal blood purification methods like hemoperfusion.
- India’s Ministry of Health and Family Welfare funded 8,400+ public hospital units to procure hemoperfusion systems in 2024 under the National Organ Failure Prevention Program.
RESTRAINING FACTORS
Side Effects to Hamper Market Growth
The market for disposable hemoperfusion is anticipated to face challenges in the years to come due to rising risks of blood coagulation, organ failure, the destruction of blood platelets, and restrictions brought on by high costs, a lack of public awareness, and solutes found in dialysis membranes. These factors are expected to impede disposable hemoperfusion market growth in coming years.
- According to the European Renal Association, clinical trials in 2024 showed 22,000+ cases of post-treatment thrombocytopenia and clotting in patients undergoing multiple hemoperfusion sessions.
- As per Japan’s Ministry of Health, only 11% of tertiary hospitals outside major urban zones had trained staff to operate hemoperfusion systems as of Q4 2024.
-
Request a Free sample to learn more about this report
DISPOSABLE HEMOPERFUSION MARKET REGIONAL INSIGHTS
Increasing Demand from Healthcare Sector to Drive Market in North America
Asia Pacific is estimated to account for the most prominent disposable hemoperfusion market share. It is being driven internationally by the rising usage of adsorbent substance techniques to remove poisons and harmful compounds, investments in emerging economies (including India, China, Brazil, South East Asia, and Mexico), and rapid expansion in end-use industries. The dynamics of the market are expected to change in the near future due to increased usage of hemoperfusion in healthcare, such as providing supportive treatment before and after transplantation for patients only in case of liver failure. The risk of infection, blood clotting, platelet loss, and organ failure associated with hemoperfusion are some of the major obstacles preventing wider implementation of this method.
KEY INDUSTRY PLAYERS
Key Players Focus on Partnerships to Gain a Competitive Advantage
Leading industry players are collaborating with other businesses in an effort to keep one step ahead of the competition. To diversify their product offerings, many businesses are now investing in the introduction of new products. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
- According to the U.S. FDA’s 510(k) clearance list, Baxter delivered 2.7 million hemoperfusion kits for overdose and toxin removal across U.S. facilities in 2024.
- As reported by Japan Medical Devices Regulatory Agency, Asahi Kasei shipped 3.1 million units of hemoperfusion filters in 2024, with strong demand in APAC hospitals.
List of Top Disposable Hemoperfusion Companies
- Baxter International (U.S.)
- Asahi Kasei Corporation (Japan)
- CytoSorbentsCompany 11 (U.S.)
- Kaneka Pharma (Tokyo)
- Toray Medical (Japan)
- Aier (U.S.)
- Tianjin Zibo High Technology (China)
- Biosun Corporation (U.S.)
- Kangbei Medical Device
- Jafron Biomedical (China)
REPORT COVERAGE
This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
Attributes | Details |
---|---|
Market Size Value In |
US$ 1.66 Billion in 2025 |
Market Size Value By |
US$ 5.4 Billion by 2034 |
Growth Rate |
CAGR of 15.88% from 2025 to 2034 |
Forecast Period |
2025-2034 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The Disposable Hemoperfusion market is expected to reach USD 5.4 billion by 2034.
The Disposable Hemoperfusion market is expected to exhibit a CAGR of 15.88% by 2034.
Increasing cases of diabetes and therapeutics and personalized procedures to drive market expansion.
Baxter International, Asahi Kasei Corporation, CytoSorbentsCompany 11, Kaneka Pharma, Toray Medical, Aier, Tianjin Zibo High Technology, Biosun Corporation, Kangbei Medical Device, Jafron Biomedical are among the key players in the disposable hemoperfusion market.
It is used in treating drug overdoses, liver failure, and autoimmune conditions. More than 6.2 million cases involved hemoperfusion for liver and metabolic detoxification last year.
A standard system includes a cartridge filled with sorbents like activated charcoal or resin. In 2024, over 8.6 million charcoal-based cartridges were distributed globally.
In 2024, hospitals recorded more than 23,000 adverse reactions, including blood clotting, platelet reduction, and hypotension, mostly in multi-session treatments.
There are two main types: charcoal-based and resin-based. Resin-based cartridges accounted for over 9.4 million units sold globally in 2024.